(VCBeat) Apr. 17, 2021 -- On April 16, 2021, Suzhou Porton Biologics Ltd. ("Portonbio"), a subsidiary focusing on gene and cell therapy of Porton Pharma Solutions Ltd. (stock abbreviation: Porton Share; stock code: 300363), announced it has closed a Series A funding, bringing the total funding raised to 400 million yuan, with participation from SDIC CMC Investment, GL Ventures, HM Capital, Huashan Ruilian Fund, Shijie Investment and other well-known investors.

Porton Pharma Solution Ltd., founded in Chongqing in July 2005, is a Chinese top-tier contract development and manufacturing organization (CDMO) that provides one-stop CDMO services for both chemical drugs from APIs to formulation and biological drugs for global pharmaceutical companies and biotechs. It is committed to building the world's leading pharma solutions platform, enabling the transformation from molecules to medicines with continuous improvements in speed and cost.

Portonbio is committed to providing end-to-end gene/therapy CDMO service for innovators from the early stage, IND filling and even commercial production in order to advance clients' product into clinics and beyond. The GMP workshop of Portonbio's first-phase project was completed and put into operation in November 2020, which can meet the needs of from process development to clinical production of plasmids, viruses and cell therapy products.

The funding will be used for the construction and operation of commercial production base, the development of the gene therapy business and GMP-compliant production, the improvement of production capacity in plasmids, viruses and cell therapy products, and the promotion of the end-to-end CDMO service platform of gene and cell therapy.

SDIC CMC Investment is a professional private equity management company jointly set up by SDIC and China Merchants Capital. The company mainly invests in the fields of intelligent manufacturing, new energy intelligent vehicles, life science, information and communication technology and others. SDIC CMC Investment is committed to promoting the green, digital and service-oriented development of the manufacturing industry, with an AUM of more than RMB100 billion.

GL Ventures was set up by private equity heavyweight Hillhouse Capital to invest in emerging startups in February 2020. GL Ventures focuses on four areas: biomedicine and medical devices, software services and initiatives in tech innovations, consumer internet and technology, and emerging consumer brands and services.